KR0163813B1 - Extraction and Purification of Active Active Ingredients from Phosphorus and Herbal Composition Containing the Extracts - Google Patents
Extraction and Purification of Active Active Ingredients from Phosphorus and Herbal Composition Containing the Extracts Download PDFInfo
- Publication number
- KR0163813B1 KR0163813B1 KR1019950026859A KR19950026859A KR0163813B1 KR 0163813 B1 KR0163813 B1 KR 0163813B1 KR 1019950026859 A KR1019950026859 A KR 1019950026859A KR 19950026859 A KR19950026859 A KR 19950026859A KR 0163813 B1 KR0163813 B1 KR 0163813B1
- Authority
- KR
- South Korea
- Prior art keywords
- phosphorus
- extract
- active ingredient
- extracting
- leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 인동으로부터 유효활성 성분을 추출하는 방법과 그 추출물을 함유한 생약조성물에 관한 것으로서, 더욱 상세하게는 한약재로 사용되는 인동의 잎과 줄기의 혼합비율을 조절하고 그로부터 유효성분의 추출방법을 특정화하므로써 소염진통 활성이 우수한 유효성분을 효율적으로 추출ㆍ정제하는 방법과 그 추출ㆍ정제된 엑기스를 함유한 생약 조성물에 관한 것이다.The present invention relates to a method for extracting an active ingredient from phosphorus and a herbal composition containing the extract, and more particularly, to adjust the mixing ratio of the leaves and stems of phosphorus used as a herbal medicine and to extract the active ingredient therefrom. The present invention relates to a method for efficiently extracting and purifying an effective ingredient having excellent anti-inflammatory analgesic activity and to a herbal composition containing the extracted and purified extract.
Description
본 발명은 인동으로부터 유효활성 성분을 추출하는 방법과 그 추출물을 함유한 생약조성물에 관한 것으로서, 더욱 상세하게는 한약재로 사용되는 인동의 잎과 줄기의 혼합비율을 조절하고 그로부터 유효성분의 추출방법을 특정화하므로써 소염진통 활성이 우수한 유효성분을 효율적으로 추출ㆍ정제하는 방법과 그 추출ㆍ정제된 엑기스를 함유한 생약 조성물에 관한 것이다.The present invention relates to a method for extracting an active ingredient from phosphorus and a herbal composition containing the extract, and more particularly, to adjust the mixing ratio of the leaves and stems of phosphorus used as a herbal medicine and to extract the active ingredient therefrom. The present invention relates to a method for efficiently extracting and purifying an effective ingredient having excellent anti-inflammatory analgesic activity and to a herbal composition containing the extracted and purified extract.
인동(忍冬)은 우리나라의 전국 산야지의 수림아래에 자생하는 인동과(Capriofoliaceae)의 반상록 덩굴성 관목 식물로서, 꽃봉오리는 '금은화'라하고 잎과 줄기는 '인동등(忍冬藤)'이라 하여 한방에서 널리 이용되어온 식물이다.Indong is a semi-evergreen vine shrub of the Capriofoliaceae family that grows under the forests of the country's wild field, and the bud is called 'Gold Silver Coin' and the leaves and stems are called 'Indongdeung'. This is a plant that has been widely used in herbal medicine.
지금까지 알려진 인동등에 함유된 유효활성 성분으로는 로니세린(Lonicerin; luteolin-7-rhamnoglucoside), 카페오일퀸산(caffeoylquinicacid), 메틸 카페에이트(methyl caffeate), 클로로겐산(chlorogenic acid), 이소-클로로겐산(iso-chlorogenic acid) 등의 플라보노이드(flavonoides) ; 오크나플라본(ochnaflavon) 등의 바이플라보노이드(biflavnoides) ; 사포닌(saponin)의 일종이 풀보토멘토사이드(fulvotomentoside) A, α-헤데린(α-hederin), 사핀도사이드(sapindoside) B 및 본 발명자 등에 의하여 규명된 신물질인 로니세로사이드(Loniceroside) A, B(한국특허공개 제94-2267호) ;로가닌(Loganin), 보겔로사이드,(Vogeloside), 에피-보겔로사이드(Epi-vogeloside) 등의 이리도이드 글리코사이드(Iridoid glycosides) 등이 함유되어 있는 것으로 밝혀졌다. 이러한 인동은 예로부터 그 탕제(湯劑)는 모든 옹저(癰疽, 속과 겉의 염증)에 유효하다 하여 관절염, 기관지염, 천식 등에 널리 이용되어 왔으며, 근자에 와서는 유행성 감기, 각종화농성 감염증, 습열로 인하여 일어나는 관절의 발적, 종창, 간독성 보호, 세포면역능력 저하의 회복에 효과가 있다고 알려져 있다.The active ingredients contained in phosphorus and the like so far known are Lonicerin (luteolin-7-rhamnoglucoside), caffeoylquinicacid, methyl caffeate, chlorogenic acid, iso-chlorogenic acid (iso flavonoids such as -chlorogenic acid; Biflavonides, such as ochnaflavon; A kind of saponin is fulvotomentoside A, α-hederin, sapindoside B, and new material Loniceroside A identified by the present inventors, B (Korean Patent Publication No. 94-2267); Contains iridoid glycosides such as Loganin, Vogeloside, Epi-vogeloside, etc. Turned out to be. These sinus has been widely used in arthritis, bronchitis, asthma, etc., since the prosthesis is effective for all scabs (inflammation of the inside and the outside), and in recent years, pandemic flu, various purulent infections, moist fever It is known to be effective in restoring joint redness, swelling, hepatotoxicity, and recovery of decreased cellular immunity.
그러나 기성 한의서(漢醫書)나 관련 문헌에서는 대부분 인동자체에 대한 한방의학적 약효에 대해서만 언급되어 있을 뿐 인동 약효성분에 관한 연구도 극히 미미하였고, 그 약효성분의 효율적인 추출방법에 관해서는 연구결과가 발표된 바 없다.However, most of the traditional Chinese medicine and related literatures mention only herbal medicines for humans themselves. It has never been.
특히, 인동의 줄기와 잎에 함유되어 있는 유효활성 성분에 관한 실험이나 채취시기에 따른 유효활성 성분의 함량변화, 그리고 소염진통효과의 최적 조건을 나타내는 유효활성 성분의 조성 등에 관해서는 연구가 이루어지지 않고 있어서 인동 추출물의 사용은 한방의 고전적 방법인 탕제방식에 의해 이용하는 실정에 불과하였다.In particular, there are no studies on the active ingredients contained in the stems and leaves of the phosphorus, the changes in the contents of the active ingredients according to the harvesting time, and the composition of the active ingredients representing the optimal condition for the anti-inflammatory analgesic effect. Since the use of phosphorus extract was only the situation to use by the traditional method of herbal medicine.
따라서, 본 발명자들은 생약성분의 추출효율을 극대화하고 인동을 보다 과학적으로 유용하게 이용하고자 노력한 결과 인동의 줄기와 잎을 활성물질의 함량이 가장 많은 생육시기에 채취하고 줄기와 잎의 첨가비율을 최적화하여 유효활성 성분을 추출하는 방법을 알아내고, 이로부터 소염진통활성이 우수한 엑기스를 과학화, 규격화하여 첨가한 생약조성물을 개발함으로써 본 발명을 완성하였다.Therefore, the present inventors have tried to maximize the extraction efficiency of the herbal ingredients and use the phosphorus more scientifically, and as a result, the stem and leaves of the phosphorus are collected at the growth period with the highest content of the active substance, and the addition ratio of the stem and the leaf is optimized. The present invention was completed by finding a method of extracting an active ingredient, and developing a herbal composition from which the extract having excellent anti-inflammatory analgesic activity was scientifically formulated and standardized.
본 발명은 인동의 채취시기, 잎과 줄기의 혼합비율을 조절하여 소염진통 생리활성이 있는 유효성분을 가장 활성이 우수한 조성으로 추출하는 방법과 그 추출유효성분을 함유한 생약조성물을 제공하는데 그 목적이 있다.The present invention is to provide a method for extracting the active ingredient with anti-inflammatory analgesic physiological activity to the most active composition by adjusting the timing of harvesting, mixing ratio of leaves and stems, and a herbal composition containing the extract active ingredient There is this.
이하, 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
본 발명은 인동으로부터 유효활성 성분을 추출ㆍ정제함에 있어서, 인동의 꽃이 지고난 후에 채취하여 건조하고 마쇄한 인동줄기와 인동의 개화기에 채취하여 건조하고 마쇄한 인동잎을 7 : 3 내지 5 : 5의 중량비로 혼합하여 물로 환류 추출한 후에 여과하고 정제하는 것을 그 특징으로 한다.In the present invention, in extracting and purifying an active ingredient from phosphorus, the dried and ground phosphorus leaves are collected after harvesting the dried phosphorus flower and the dried and ground phosphorus leaves are collected in the flowering period of the phosphorus. The mixture is mixed at a weight ratio of 5 to reflux with water, and then filtered and purified.
또한, 본 발명은 인동으로부터 추출한 로니세로사이드(Loniceroside) A가 0.5∼3.0중량%, 로니세로사이드 B 가 0.5∼2.0중량%, 로니세린(Lonicerin)이 0.5∼3.0중량%, 로가닌(Loganin)이 2.0∼5.0중량% 함유되어 있는 생약조성물을 포함한다.In addition, the present invention is 0.5-3.0% by weight of Loniceroside A extracted from phosphorus, 0.5-2.0% by weight of Lonieroside B, 0.5-3.0% by weight of Lonicerin, Loganin Herbal composition containing 2.0 to 5.0% by weight).
이와 같은 본 발명을 더욱 상세히 설명하면 다음과 같다.Referring to the present invention in more detail as follows.
본 발명은 인동의 줄기와 잎으로부터 소염진통 생리활성이 우수한 유효성분을 추출ㆍ정제하는 방법으로서, 본 발명에서 사용한 인동의 줄기와 잎은 각각 특정시기에 채취한 것을 사용하므로써 유효성분함량을 극대화시킬 수 있다.The present invention is a method for extracting and purifying an active ingredient having excellent anti-inflammatory analgesic physiological activity from the stems and leaves of phosphorus, and the stems and leaves of the phosphorus used in the present invention can be maximized by using the ones collected at specific times. Can be.
본 발명에 따르면, 인동잎은 인동의 꽃이 만개(滿開)한 직후에 채취하는 것이 가장 바람직한데, 우리나라 계절로는 대개 6월말에서 7월 초순에 해당되는 시기이다.According to the present invention, it is most preferable to collect the honeysuckle leaves immediately after the flowers of the honeysuckle are in full bloom, and the seasons in Korea usually correspond to the end of June to the beginning of July.
또한 인동 줄기는 인동의 꽃이 완전히 지고난 연후에 채취하는 것이 가장 바람직한 바, 우리나라 계절로는 대개 10월에서 12월 사이에 해당되는 시기이다.In addition, it is most preferable to collect the stem of the stem after the flower of Indong has completely disappeared, which is usually between October and December.
이와같이 가장 적당한 시기에 채취한 인동잎과 줄기를 각각 잘 건조시키고 적당한 크기로 마쇄하여 혼합하는데, 그 혼합비율은 줄기와 잎의 첨가 중량비가 7 : 3 내지 5 : 5가 되도록 한다.In this way, the leaves and stems collected at the most appropriate time are well dried and ground to a suitable size and mixed. The mixing ratio is such that the weight ratio of the stem and the leaves is 7: 3 to 5: 5.
본 발명에 따르면, 인동의 줄기와 잎의 채취시기에 따라 그에 함유되어 있는 유효성분의 함량에 커다란 차이를 보여주는데, 인동줄기의 경우 동절기에 해당하는 시기 즉, 꽃이 완전히 지고난 연후가 평소의 경우에 비해 약 2배 가량 유효활성 성분이 증가된 것으로 보여주고 있으며 인동잎의 경우는 꽃이 만개한 직후가 약 3∼5배 가량의 유효활성 성분 증가를 나타낸다.According to the present invention, there is a big difference in the content of the active ingredient contained therein according to the harvesting time of the stem and leaves of the honeysuckle, in the case of the honeysuckle stem, which corresponds to the winter season, that is, after the flower has been completely lost Compared to that, the active ingredient was increased about 2 times, and in case of artificial leaves, the active ingredient was increased about 3 to 5 times immediately after the flower was in full bloom.
또한, 본 발명에서는 인동의 채취시기와 함께 인동줄기와 잎의 혼합비율도 중요한 의미를 갖는다. 왜냐하면 유효활성 성분의 함량이 가장 높은 시기에 채취한 줄기와 잎의 비율에 따라서 그 소염진통 생리활성에 커다란 변화를 가져오며 이는 아마도 가장 적당한 비율에서의 상승효과(Synergic effect) 때문인 듯하다. 따라서, 줄기와 잎의 사용비율이 적당한 범위인 경우를 선택해야 하는데, 본 발명에 따르면 줄기가 잎보다 약간 많은 중량으로 혼합된 경우가 가장 바람직한 소염 및 진통활성을 나타내는 것으로 밝혀졌다.In addition, in the present invention, the mixing ratio of the phosphorus stem and leaves with the harvesting time of the phosphorus also has an important meaning. Because of the ratio of stem and leaves collected at the highest active ingredient content, the anti-inflammatory analgesic changes greatly, probably due to the synergistic effect at the most suitable ratio. Therefore, the case where the ratio of use of the stem and the leaf should be selected should be selected. According to the present invention, it was found that the case where the stem was mixed at a slightly higher weight than the leaf showed the most desirable anti-inflammatory and analgesic activity.
따라서, 본 발명에서는 적당한 시기에 채취된 인동의 줄기와 잎의 사용비율을 중량비로 7 : 3 ∼ 5 : 5가 되도록 하는 경우가 가장 바람직하다는 중요한 사실을 밝혀냈다. 여기서 상기 인동잎과 줄기의 채취시기가 다르거나 첨가중량비가 상기 비율을 벗어나면 소염진통 생리활성 유효성분의 함량변화를 초래하여 약효가 떨어지는 문제가 있다.Therefore, in the present invention, it was found that it is most preferable that the use ratio of the stem and leaves of the phosphorus collected at a suitable time is set to 7: 3 to 5: 5 by weight. Here, when the harvesting time of the copper leaf and the stem is different or the added weight ratio is out of the ratio, there is a problem that the drug efficacy is lowered by causing the content change of the anti-inflammatory analgesic physiologically active ingredient.
본 발명에서는 상기 혼합된 인동잎과 줄기의 생약원료를 물로 추출하는데, 생약원료 중량의 8∼12배의 물을 가하여 5시간 정도 환류 추출한 후 여과하여 여액을 모으고, 다시 잔사를 생약원료 중량의 3∼7배의 물을 가하여 가온후 여과하여 여액을 앞의 여액과 혼합함으로써 물 추출효율을 높인다.In the present invention, the mixed herbal leaves and stems of the herbal medicines extracted with water, 8 to 12 times the weight of the herbal raw material is added by reflux extraction for about 5 hours and then filtered to collect the filtrate, and the residue 3 again the weight of the herbal raw material weight The water extraction efficiency is increased by adding ˜7 times of water, heating and filtration and mixing the filtrate with the previous filtrate.
여기서 물로 추출함에 있어 물의 양이 너무 적어지게 되면 교반이 어렵게 되고 추출물의 용해도가 낮아져 추출효율이 떨어지게 되고, 지나치게 많은 경우는 다음 정제단계에서 사용되는 저급알콜용매의 사용량이 많아져 경제적으로 불리하게 되고 취급상에 애로점이 발생하게 되며, 재차 추출하는 것 역시 추출효율을 높이기 위한 것으로서 대량 생산시 효과적으로 여과를 한다고 하더라도 생약자체의 수분함유랑이 높기 때문에 손실이 발생하여 1차 추출만으로는 추출만으로는 추출효율이 떨어지므로 이것을 방지하기 위함이다.If the amount of water is too small in the extraction with water, it is difficult to stir and the solubility of the extract is lowered, the extraction efficiency is reduced, if too much, the amount of the lower alcohol solvent used in the next purification step becomes more economically disadvantageous. Defects occur in handling, and the extraction again is to improve the extraction efficiency. Even though the filtration is effective in mass production, the loss of the herbal medicine is high because the water content of the herbal medicine is high. This is to prevent this.
이와같이 인동으로부터 추출된 유효성분 추출액에는 엽록소와 불필요한 지방산등 불순물이 포함되어 있어서 정제가 필요한 바, 본 발명에서는 추출하여 얻어진 여액에다 그 여액과 같은량의 수포화 저급알콜을 넣어 층분리에 의해 용매분획을 얻는다.As such, the active ingredient extract extracted from phosphorus contains impurities such as chlorophyll and unnecessary fatty acids, and thus purification is necessary. In the present invention, the same fraction of the saturated filtrate as the filtrate is added to the filtrate obtained by extraction and solvent fractionation is performed by layer separation. Get
이때 사용되는 용매인 수포화 저급알콜은 저급알콜의 포화수용액으로서 저급알콜에 증류수를 가하고 교반시킨 후 정체시켜 물로 포화된 저급알콜층을 취한 것으로 이때. 저급알콜로는 예컨대 프로필알콜, 부틸알콜 등이 사용가능하며, 층분리는 2∼3회 실시한다.At this time, the saturated alcohol used as a saturated alcohol is a saturated aqueous solution of a lower alcohol. The lower alcohol is stirred by adding distilled water to the lower alcohol, stirring, and stagnating. As the lower alcohol, for example, propyl alcohol, butyl alcohol and the like can be used, and the layer separation is performed 2-3 times.
만일 저급 알콜로 용매분획을 얻음에 있어서, 소량의 저급알콜을 사용하게 되면 정제 효율이 떨어져 엑기스 수율이 낮아지게 되고, 과량의 저급알콜을 사용하게 되면 로니세로사이드(Loniceroside) A, B 등과 같은 유효생리활성 성분함량이 낮아져 활성이 떨어지게 됨으로써 효율적이지 못하게 된다. 그러므로 유효생리활성 성분 함량을 일정 수준으로 유지하여 우수한 생리활성 효과를 나타내기 위해서는 여액과 동량의 저급알콜 용매로 2회 정도 충분리 하는 것이 가장 바람직하다.If a lower alcohol is used to obtain a fraction of the lower alcohol, the lower the extraction efficiency, the lower the extraction yield, and the higher the lower alcohol, the more effective the Loniceroside A, B, etc. The bioactive component content is lowered and the activity is lowered, which makes it inefficient. Therefore, in order to maintain an effective physiologically active ingredient content at a certain level and to exhibit an excellent physiological activity effect, it is most preferable to suffice twice with a filtrate and the same amount of a lower alcohol solvent.
또한, 추출물중에 불필요한 지방산과 클로로필 등의 비극성 물질을 제거하고 잔존한 저급알콜용매량을 제한하기 위해 저급알콜용매분획을 60∼70℃으로 감압농축한 후, 얻어진 엑기스 중량의 20 30배의 물을 가하여 공비농축하고 재차 동량의 물을 가하여 막여과에 의해 불용성물질을 제거한 다음 동결건조함으로써 분말상태의 엑기스를 얻는다.In addition, in order to remove unnecessary fatty acids such as fatty acids and chlorophyll in the extract and to limit the remaining amount of lower alcohol solvent, the lower alcohol solvent fraction was concentrated under reduced pressure at 60 to 70 ° C., and water of 20 to 30 times the weight of the extract was obtained. After adding azeotropically, add an equal amount of water to remove insoluble matter by membrane filtration and freeze-drying to obtain a powdery extract.
이렇게 정제된 저급알콜 분획을 농축 건조함에 있어서 물로 공비 농축을 시키지 않으면 잔존하는 저급알콜의 함량이 지나치게 높아져 의약품 원료로써 사용상에 문제점이 있고, 지방산 및 비극성 물질의 막여과에 의한 제거과정을 거치지 않을 경우 엑기스 농축시 농축시간 지연 및 건조상태의 불량을 초래할 수 있기 때문에 엑기스 순도유지 및 이물질 제거를 위하여 막여과(membrane filter)를 행하는 것이다.In this case, if the azeotropic concentration of the purified lower alcohol fraction is not concentrated with water, the residual lower alcohol content becomes too high, which causes problems in use as a pharmaceutical raw material, and does not undergo the removal process by membrane filtration of fatty acids and nonpolar substances. Membrane filters are performed to maintain the purity of the extract and to remove foreign substances, as the concentration of the extract may cause a delay in the concentration time and a poor drying condition.
이렇게 하여 간단하고 경제적인 방법으로 얻어진 엑기스는 사상의학, 동의보감등의 기성 한의서에 수록된 인동을 이용한 탕제보다 소염작용이 상당히 우수할 뿐만 아니라 진통작용 또한 겸비하고 있어 효과적인 소염, 진통 생리활성제로 유용하게 적용될 수 있다.The extract obtained by this simple and economic method is not only excellent in anti-inflammatory action but also analgesic action compared to the anti-inflammatory medicines in the traditional Chinese medicine, such as Sasang Medicine, Dong-Bo-gam. Can be.
상기와 같은 본 발명에 따른 방법으로 인동의 잎과 줄기로부터 추출된 규격화된 엑기스의 소염진통 유효생리활성물질을 분석한 결과 발명자들에 의해 최초로 규명된 신물질인 로니세로사이드(Loniceroside) A, B 를 비롯하여 이미 알려진 성분인 로가닌(Loganin), 로니세린(Lonicerin) 등이 함유되어 있다.As a result of analyzing the anti-inflammatory analgesic effective physiologically active substances of the standardized extract extracted from the leaves and stems of the phosphorus by the method according to the present invention as described above, the new substance Loniceroside A, B was first identified by the inventors. In addition, known ingredients such as Loganin and Loginerin (Lonicerin) are contained.
그런데, 본 발명에 따르면 소염진통 활성효과는 로니세로사이드 A가 0.5∼3.0중량%, 로니세로사이드 B가 0.5∼3.0중량%로 함유되어 있는 경우가 가장 바람직한 것으로 밝혀졌다.However, according to the present invention, the anti-inflammatory analgesic effect was found to be the most preferable in the case that 0.5-3.0% by weight of Ronicereroside A, 0.5-3.0% by weight of Ronnieseroside B.
즉, 인동에서 추출한 유효활성 성분 조성은 특정성분의 배합비율이 일정한 조성 범위에서 가장 우수한 활성을 나타낸다는 사실을 알게되었다.In other words, it was found that the active ingredient composition extracted from phosphorus showed the best activity in a certain composition range of the compounding ratio.
또한, 상기 방법으로 추출 정제된 엑기스에 위와같은 로니세로사이드 A와 B의 조성과 함께 로니세린 0.5∼2.0중량%와 로가닌 2.0∼5.0중량%가 함유되어 있어서 활성이 더욱 우수한 효과를 나타내는 것으로 나타났다.In addition, the extract extracted and purified by the above method contains 0.5-2.0% by weight of lonicerin and 2.0-5.0% by weight of loganine together with the above-mentioned compositions of Loneroside A and B. appear.
이와같은 사실은 놀랍게도 본 발명의 추출 정제방법에 따라 인동의 줄기와 잎을 채취하고 혼합하여 그로부터 추출을 시행하는 경우와 일치한다는 사실이 밝혀졌다.This fact was surprisingly found to be consistent with the case of extracting and mixing the stem and leaves of the phosphorus according to the extract purification method of the present invention.
따라서, 본 발명에 따른 추출 정제방법으로 얻어낸 분말엑기스로 생약조성물을 제조하여 사용하는 경우 소염진통제로 유용하게 이용될 수 있다.Therefore, when preparing a herbal composition using the powder extract obtained by the extraction and purification method according to the present invention can be usefully used as an anti-inflammatory analgesic.
본 발명에 따른 분말엑기스로 제조되는 생약조성물은 인동 분말엑기스를 통상의 방법으로 제형화하여 정제, 연질캅셀, 주사제 등의 형태로 투여할 수 있으며, 이때 사용되는 기제, 예컨대 락토오스(Lactose), 미세결정 셀룰로오즈(Microcrystalline Cellulose), 마그네슘 스테아린산(Magnesium Stearate) 등의 기제성분과 인동 분말엑기스를 1.5 : 1의 비율로 사용하면 기존의 것에 비해 월등한 소염진통 활성을 나타내게 된다.The herbal composition prepared from the powder extract according to the present invention may be formulated in a conventional manner, and then administered in the form of tablets, soft capsules, injections, etc., and bases such as lactose, fine When using a base ingredient such as crystalline cellulose (Microcrystalline Cellulose), magnesium stearate (Magnesium Stearate) and phosphorus powder extract in a ratio of 1.5: 1, it exhibits superior anti-inflammatory analgesic activity compared to the conventional one.
특히, 본 발명의 생약조성물을 인체에 투여하는 경우 천연 추출물인 관계로 다른 합성의약품에 비해 부작용의 염려가 거의 없으며, 이러한 부작용 감소의 일예로서는, 일반적인 NSAID(Non Steroidal Anti Inflammatory Drug)계 약물이 나타내는 위장장애 및 궤양유발 부작용에 대한 동물모델실험에서 입증되었다.Particularly, when the herbal composition of the present invention is administered to the human body, there is little concern about side effects compared to other synthetic drugs because it is a natural extract, and as an example of such side effects reduction, a non-steroidal anti-inflammatory drug (NSAID) -based drug is represented. It has been demonstrated in animal model experiments for gastrointestinal disorders and ulcerative side effects.
즉, 인도메타신(Indomethacin), 에틸알콜(EtOH) 및 염산(HCI)으로 유발시킨 궤양억제 시험결과에서도 알 수 있듯이 본 발명에서 제조된 인동추출물에서는 이러한 궤양유발 인자에 의한 궤양유발을 억제하는 효과가 탁월하였으며(실험예 참조), 마우스(mouse) 및 랫트(rat)에 대한 급성 독성실험결과 전혀 무독한 것으로 판명되었다. (LD50= 5g ext's/Kg 이상, 생약학회지 Vol. 25, No.4, 1994).That is, as can be seen from the results of the ulcer inhibition test induced by indomethacin, ethyl alcohol (EtOH) and hydrochloric acid (HCI), the effect of inhibiting the ulcer induction caused by the ulcer inducing factor in the human extract prepared in the present invention. Was excellent (see Experimental Examples), and acute toxicity studies in mice and rats proved completely non-toxic. (LD 50 = 5 g ext's / Kg or more, Journal of Pharmacognosy Vol. 25, No. 4, 1994).
상술한 바와같이, 본 발명에 따르면 인동으로부터 유효생리활성 성분을 추출 정제함에 있어서, 기존에 알려진 추출방법과는 달리 인동의 줄기와 잎을 특정시기에 채취하고 일정비율로 혼합한 원료를 이용하여 추출·정제를 시행하게 되면 종래방법에 의한 일반적 추출방법으로 얻어진 추출물에 비하여 현격한 효능 차이가 있는 추출물을 얻을 수 있게되어 과학적인 천연물 추출이 가능하다. 또한, 종래에 한약탕제 등의 형태로만 이용되었던 인동추출물을 투여가 편리한 연고제, 정제, 주사제 등의 제형으로 투여가능케할 수 있는 효과가 있다.As described above, according to the present invention, in extracting and purifying the active physiologically active ingredient from phosphorus, unlike the conventionally known extraction method, the stem and leaves of the phosphorus are extracted at a specific time and extracted using a raw material mixed at a predetermined ratio. · Purification is possible to obtain an extract with a noticeable difference in effect compared to the extract obtained by the conventional extraction method according to the conventional method, it is possible to extract scientific natural products. In addition, there is an effect that can be administered in the form of a convenient ointment, tablets, injections and the like, which is conventionally used only in the form of medicinal herbs such as herbal medicine.
이하, 본 발명을 실시예에 의거 더욱 상세히 설명하면 다음과 같은 바, 본 발명이 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following Examples, which are not intended to limit the present invention.
[참고예 1]Reference Example 1
인동줄기와 잎의 적절한 채취시기를 확인하기 위하여 소염, 진통 생리활성 물질인 로니세로사이드 A, 로니세로사이드 B, 로니세린, 로가닌들 중에서 잎의 로니세로사이드 A, B 함량과 줄기의 로가닌 함량의 매월별 변화를 HPLC로 분석하여 그 결과를 다음 표 1에 나타내었다.To determine the proper timing of harvesting of stems and leaves, Ronicerose A, B content of leaf and stem of Rosincerside A, Roniceroseoside B, Roniserine, and Roganin among anti-inflammatory and analgesic bioactive substances The monthly change in the content of garnin was analyzed by HPLC and the results are shown in Table 1 below.
또한 6월, 7월의 잎에 대한 유효성분 분석과 11월, 12월의 줄기에 대한 유효성분 분석결과는 다음과 같다.In addition, the results of the analysis of the active ingredients for the leaves in June and July and the results of the analysis of the active ingredients for the stems in November and December are as follows.
[참고예 2]Reference Example 2
인동에서 추출된 유효약효성분의 함량은 잎의 경우 꽃이 만개한 직후인 6∼7월, 그리고 줄기의 경우 꽃이 지고난 후인 11∼12월에 채취된 것에서 많은 것을 확인하고, 이 시기의 줄기와 잎을 채취하여 그 혼합비율별 소염, 진통 생리활성 변화를 실험한 결과를 다음 표 2에 나타내었다.The content of the active drug extracted from indong was confirmed in the extracts from June to July immediately after the flowers bloomed in the case of leaves, and from November to December after the flowers had fallen from the stems. And leaves were collected and the results of experiments on the anti-inflammatory, analgesic bioactive changes according to the mixing ratio is shown in Table 2 below.
[실시예 1]Example 1
경북 안동 지역에서 11월말에 채취한 인동줄기를 잘 건조시켜 1.0∼1.5cm 크기로 세절하고, 동지역에서 6월말에 채취한 인동잎을 잘 건조시켜 3∼5mm로 마쇄한 후 줄기 700g과 잎 300g을 취하여 8ℓ의 물을 가한 후, 잘 교반하여 주면서 5시간 동안 환류 추출후 여액을 모으고, 잔사를 모아 7 의 물을 가한 후, 2시간동안 가온 추출하여 잎의 여액과 혼합함으로써 물추출 효율을 높이고, 추출여액과 동량의 수포화 n-부틸알콜을 가하여 2회 충분리한 후 n-부틸알콜층을 모아 60∼70℃로 감압농축한 다음, 0.8 의 증류수를 가하여 공비농축 한 후 동량의 증류수를 가하여 용해시키고 막여과 하여 불용성 성분을 제거한 다음 동결건조하여 41g의 엑기스를 얻었다. 이 엑기스에 잔류하는 부틸알콜량은 159ppm이었고, 유효성분조성은 로니세로사이드(Loniceroside) A 1.34%, 로니세로사이드(Loniceroside) B 1.52%, 로니세린(Lonicerin) 1.1%, 로가닌(Loganin) 4.96%이었다.Dry the dried stems collected in Andong, Gyeongbuk in the end of November, and cut them into 1.0 ~ 1.5cm size, and dry the dried leaves collected at the end of June in the same area and crush them to 3-5mm, and then stalk 700g and leaves 300g. 8 liters of water was added to the mixture, and the mixture was extracted with reflux for 5 hours while stirring well, the residue was collected and added with water of 7, and then extracted by heating for 2 hours and mixed with the filtrate of the leaves to increase water extraction efficiency. After adding the extract filtrate with the same amount of saturated n-butyl alcohol and saturating twice, the n-butyl alcohol layer was collected and concentrated under reduced pressure at 60-70 ° C., followed by azeotropic concentration with 0.8 distilled water, followed by addition of the same amount of distilled water. Dissolved and membrane filtered to remove insoluble components and then lyophilized to obtain 41g of extract. The amount of butyl alcohol remaining in the extract was 159 ppm, and the active ingredient composition was 1.34% of Loniceroside A, 1.52% of Loniceroside B, 1.1% of Lonicerin, and Loganin. 4.96%.
[실시예 2]Example 2
경북 안동 지역에서 11월말에 채취한 인동줄기를 잘 건조시켜 1.0∼1.5cm 크기로 세절하고, 동지역에서 6월말에 채취한 인동잎을 잘 건조시켜 3∼5mm로 마쇄한 후 줄기 500g과 잎 500g을 취하여 12ℓ의 물을 가한 후, 잘 교반하여 주면서 5시간동안 환류 추출후 여액을 모으고, 잔사를 모아 3ℓ의 물을 가한 후, 2시간동안 가온 추출하여 잎의 여액과 혼합함으로써 물추출 효율을 높이고, 추출여액과 동량의 수포화 n-부틸알콜을 가하여 2회 층분리한 후 n-부틸알콜층을 모아 60∼70℃로 감압농축한 다음, 1ℓ의 증류수를 가하여 공비농축 한 후 동량의 증류수를 가하여 용해시키고 막여과 하여 불용성 성분을 제거한 다음 동결건조하여 52g의 엑기스를 얻었다. 이 엑기스에 잔류하는 부틸알콜량은 178ppm이었고, 유효성분 조성은 로니세로사이드 1.89%, 로니세로사이드 2.08%, 로니세린 1.56%, 로가닌 3.34%이었다.Dry the dried stems collected at the end of November in Andong, Gyeongbuk, and cut them into 1.0 ~ 1.5cm size, and dry the dried leaves collected at the end of June at the end of June to crush them to 3-5mm, and then stalk 500g and leaves 500g. 12 liters of water was added, and the mixture was extracted with reflux for 5 hours while stirring well, and the residue was collected and 3 liters of water was added. Then, the mixture was heated and extracted for 2 hours to increase water extraction efficiency. After extracting the filtrate with the same amount of saturated n-butyl alcohol and dividing the layer twice, the n-butyl alcohol layer was collected and concentrated under reduced pressure at 60-70 ° C., and then azeotropically concentrated with 1 L of distilled water. The resultant was dissolved, membrane filtered to remove insoluble components, and lyophilized to obtain 52 g of extract. The amount of butyl alcohol remaining in the extract was 178 ppm, and the active ingredient composition was 1.89% of rosineroside, 2.08% of rosineroside, 1.56% of rosinerine, and 3.34% of roganine.
[실시예 3]Example 3
경북 안동 지역에서 11월말에 채취한 인동줄기를 잘 건조시켜 1.0∼1.5cm 크기로 세절하고, 동지역에서 6월말에 채취한 인동잎을 잘 건조시켜 3∼5mm로 마쇄한 후 줄기 650g과 잎 350g을 취하여 10ℓ의 물을 가한 후, 잘 교반하여 주면서 5시간동안 환류 추출후 여액을 모으고, 잔사를 모아 5ℓ의 물을 가한 후, 2시간동안 가온 추출하여 잎의 여액과 혼합함으로써 물추출 효율을 높이고, 추출여액과 동량의 수포화 n-부틸알콜을 가하여 2회 층분리한 후 n-부틸알콜층을 모아 60∼70℃로 감압농축한 다음, 1.2ℓ 의 증류수를 가하여 공비농축 한 후 동량의 증류수를 가하여 용해시키고 막여과 하여 불용성 성분을 제거한 다음 동결건조하여 44g의 엑기스를 얻었다. 이 엑기스에 잔류하는 부틸알콜량은 198ppm이었고, 유효성분조성은 로니세로사이드 A 1.47%, 로니세로사이드 B 1.78%, 로니세린 1.32%, 로가닌 4.28%이었다.Dry the dried stems collected in Andong, Gyeongbuk at the end of November and cut them into 1.0 ~ 1.5cm size, and dry the dried leaves collected at the end of June at the end of June. Take 10 liters of water, add stirring, and stir well for 5 hours while extracting the reflux for 5 hours, collect the residue, add 5 liters of water, and then extract the mixture for 2 hours with warming to increase water extraction efficiency. After extracting the filtrate with the same amount of saturated n-butyl alcohol and separating the layer twice, the n-butyl alcohol layer was collected and concentrated under reduced pressure at 60-70 ° C., followed by azeotropic concentration with 1.2 L of distilled water. It was added to dissolve, membrane filtration to remove the insoluble components and then lyophilized to obtain 44g of extract. The amount of butyl alcohol remaining in the extract was 198 ppm, and the effective composition was 1.47% of roroniseroside A, 1.78% of roroniseroside B, 1.32% of roniserine, and 4.28% of roganine.
[비교예 1]Comparative Example 1
시중에서 구입한 인동등을 표준탕액법으로 물 추출한후 여과하여 여액을 동결건조한 엑기스를 비교예 1로 하였다. 이때 유효성분조성은 로니세로사이드 A 0.03%, 로니세로사이드 B 0.05%, 로니세린 0.07%, 로가닌 0.92%이었다.The extract obtained by filtration and freeze-drying the filtrate after extracting water from the commercially available phosphorus etc. by the standard liquid solution method was made into Comparative Example 1. At this time, the effective cohesiveness was Roniseroside A 0.03%, Ronisseroside B 0.05%, Roniserin 0.07%, Loganin 0.92%.
[비교예 2]Comparative Example 2
상기 비교예 1의 추출방법대로 물 추출후 여액을 동량의 n-부틸알콜로 2회 추출후 n-부틸알콜 층을 60∼70℃로 감압농축 하고 물로 공비농축 후 물에 용해시켜 막여과 함으로써 불용성 물질을 제거한 다음에 그 여액을 동결건조하여 얻은 엑기스를 비교예 2로 하였다. 이때 유효성분조성은 로니세로사이드 A 0.16%, 로니세로사이드 0.21%, 로니세린 B 0.31%, 로가닌 3.78% 이었다.After extracting the filtrate twice with the same amount of n-butyl alcohol and extracting the filtrate twice according to the extraction method of Comparative Example 1, the n-butyl alcohol layer was concentrated under reduced pressure at 60-70 ° C., azeotropically concentrated with water, and dissolved in water to make membrane insoluble. After removing the substance, the extract obtained by lyophilization of the filtrate was set to Comparative Example 2. At this time, the effective cohesiveness was 0.16% of rosineroside A, 0.21% of rosineroside, 0.31% of rosinerine B, and 3.78% of roganin.
[실험예 1]Experimental Example 1
상기 실시예 3의 엑기스와 비교예 1, 2에서 조제한 엑기스의 급성 소염 활성 비교로써 마우스 귀 부종법(Mice ear edema model test)을 다음 실험방법과 같이 실시하여 그 결과를 다음 표 3, 4에 나타내었다.As a comparison of the acute anti-inflammatory activity of the extract prepared in Example 3 and Comparative Examples 1 and 2, the mouse ear edema model test (Mice ear edema model test) was carried out as shown in the following experimental methods and the results are shown in the following Tables 3 and 4 It was.
실험방법 : 마우스에 각각의 인동추출물을 경구투여하고 1시간 후 2.5% 크로톤오일(croton oil) 또는 2% 아라키돈산(Arachidonic acid)을 양쪽귀에 바르고 크로톤오일의 경우 5시간 후, 아라키돈산의 경우는 1시간 후 각각의 귀 두께를 두께 측정기(Dial thickness gauge)로 측정하였다. 대조군은 인동추출물 대신 멸균 증류수를 경구투여 하였다.Experimental Method: After 1 hour oral administration of each phosphorus extract to mice, 2.5% croton oil or 2% arachidonic acid was applied to both ears and 5 hours after croton oil, and for arachidonic acid. After 1 hour each ear thickness was measured with a dial thickness gauge. The control group was orally administered sterile distilled water instead of phosphorus extract.
[실험예 2]Experimental Example 2
상기 실시예 3의 엑기스와 비교예 1, 2에서 조제한 엑기스의 만성 소염 활성 비교로서 만성염증(Adjuvant induced Arthritis Model Test)를 다음 실험방법과 같이 실시하여 다음 표 5에 나타내었다.Chronic inflammation (Adjuvant induced Arthritis Model Test) as a comparison of the chronic anti-inflammatory activity of the extract prepared in Example 3 and Comparative Examples 1 and 2 shown in Table 5 below.
실험방법 : 미네랄 오일(Heavy mineral oil)에 현탁(suspension) 시킨 열처리된 마이코박테리움 부틸리쿰(Mycobacteriun buthylicum)을 랫트의 오른쪽 발에 0.6mg/Rat로 주사하여 만성 부종을 유도하였고, 물치환(water-displacement)법을 사용하여 부종정도를 측정하였으며 안동 추출물은 18일간 매일 경구투여 하였다.Experimental Method: Inject chronically edible mycobacteriun buthylicum suspended in mineral mineral oil at 0.6mg / Rat in rat's right foot to induce chronic edema. Edema was measured using water-displacement method. Andong extract was orally administered daily for 18 days.
[실험예 3]Experimental Example 3
상기 실시예 3의 엑기스와 비교예 1, 2에서 조제한 엑기스의 통증억제 효력 비교로서 초산 유도 라이딩 테스트(Acetic acid induced writhing test)를 다음 실험 방법과 같이 실시하여 그 결과를 다음 표 6에 나타내었다.As a comparison of the pain inhibitory effect of the extract prepared in Example 3 and Comparative Examples 1 and 2, the acetic acid induced writhing test was carried out as in the following experimental method, and the results are shown in Table 6 below.
실험방법 : ICR계 마우스에 인동추출물을 경구투여하고 1시간 후 0.6 초산(aceticacid)을 0.1 10 체중(Body weight)의 용량으로 복강주사하고, 주사 후 10분후부터 10분간 각각의 마우스가 나타내는 통증 반응인 비틀림(writhing)횟수를 관찰하였다.Experimental Method: After 1 hour oral administration of phosphorus extract to ICR mice, intraperitoneal injection of 0.6 acetic acid at a dose of 0.1 10 body weight, and pain response of each mouse 10 minutes after injection for 10 minutes. The number of writhing was observed.
[실험예 4]Experimental Example 4
상기 실시예 3의 엑기스와 비교예 1,2에서 조제한 엑기스의 인도메타신(Indomethacin), 에틸알콜(EtOH) 및 염산(HCI)으로 유발시킨 궤양억제효과를 비교하기 위해 다음 실험방법과 같이 실시하여 그 결과를 다음 표 7,8에 나타내었다.In order to compare the ulcer inhibition effect induced by the extract of Example 3 and the extract prepared in Comparative Examples 1, 2, Indomethacin, ethyl alcohol (EtOH) and hydrochloric acid (HCI) as in the following experimental method The results are shown in the following Table 7,8.
실험방법 : 24시간 절식시킨 랫트에 비교 약물을 경구투여시키고, 1시간 후에 궤양을 유발시키기 위하여 인도메타신 또는 에틸알콜 및 염산조제액을 경구투여하여 궤양을 유발시키고, 1시간 후에 위를 적출하여 3% 포르말린용액(Formalin solution)에 30분간 방치시킨 후 이미지 분석기(Image analyzer)를 이용하여 궤양면적을 산출한 후, 대조군 대비 궤양 면적 감소를 백분율로 나타내었다.Experimental method: Rats fasted for 24 hours were orally administered with a comparative drug, and after 1 hour to induce ulcer by oral administration of indomethacin or ethyl alcohol and hydrochloric acid solution, and after 1 hour, the stomach was extracted After leaving it in a 3% formalin solution for 30 minutes, the ulcer area was calculated using an image analyzer, and then the ulcer area reduction was shown as a percentage.
[제조예 1][Production Example 1]
상기 실시예 3에서 얻어진 분말엑기스를 이용하여 다음과 같은 조성으로 경구투여용 정제(규격화된 Ext's 100mg)를 제조하였다.Using the powder extract obtained in Example 3 to prepare a tablet for oral administration (standardized Ext's 100mg) with the following composition.
[제조예 2][Production Example 2]
상기 실시예 3에서 얻어진 분말엑기스를 이용하여 다음과 같은 조성으로 연고제를 제조하였다.Using the powder extract obtained in Example 3, an ointment was prepared in the following composition.
[제조예3][Production Example 3]
상기 실시예 3에서 얻어진 분말엑기스를 이용하여 다음과 같은 조성으로 주사제를 제조하였다.An injection was prepared in the following composition using the powder extract obtained in Example 3.
Claims (4)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR94-24803 | 1994-09-29 | ||
| KR19940024803 | 1994-09-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960010017A KR960010017A (en) | 1996-04-20 |
| KR0163813B1 true KR0163813B1 (en) | 1998-12-01 |
Family
ID=26630590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950026859A Expired - Fee Related KR0163813B1 (en) | 1994-09-29 | 1995-08-28 | Extraction and Purification of Active Active Ingredients from Phosphorus and Herbal Composition Containing the Extracts |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR0163813B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004024172A1 (en) * | 2002-09-11 | 2004-03-25 | Sk Chemicals, Co., Ltd. | Extraction and purification method of active constituents from stem of lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug |
| KR100672036B1 (en) * | 1999-01-22 | 2007-01-19 | 에스케이케미칼주식회사 | Asthma Treatments with Honey Extract |
| WO2011071296A3 (en) * | 2009-12-07 | 2011-10-13 | Pharmaking Co., Ltd. | Anti-inflammatory pharmaceutical composition comprising extracts from broussonetia papyrifera and lonicera japonica |
-
1995
- 1995-08-28 KR KR1019950026859A patent/KR0163813B1/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100672036B1 (en) * | 1999-01-22 | 2007-01-19 | 에스케이케미칼주식회사 | Asthma Treatments with Honey Extract |
| WO2004024172A1 (en) * | 2002-09-11 | 2004-03-25 | Sk Chemicals, Co., Ltd. | Extraction and purification method of active constituents from stem of lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug |
| US7314644B2 (en) | 2002-09-11 | 2008-01-01 | Sk Chemicals Co., Ltd. | Extraction and purification method of active constituents from stem of Lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug |
| WO2011071296A3 (en) * | 2009-12-07 | 2011-10-13 | Pharmaking Co., Ltd. | Anti-inflammatory pharmaceutical composition comprising extracts from broussonetia papyrifera and lonicera japonica |
Also Published As
| Publication number | Publication date |
|---|---|
| KR960010017A (en) | 1996-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2948536B2 (en) | Methods for extracting biologically effective ingredient from compounded medicinal plant and purifying it, and their extract components | |
| KR20080038127A (en) | Cynara scolymus extracts, the use thereof and formulations containing them | |
| CN101484179B (en) | Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases | |
| JP2006510592A (en) | Extraction and purification method of active component of honeysuckle (LonicerajaponicaThumb.) Stem, its use for anti-inflammatory analgesic | |
| CN102186485B (en) | Pharmaceutical composition for preventing and treating inflammatory diseases, containing an ethyl acetate fraction of dried extract of trachelospermi caulis as an active ingredient, and method for producing the fraction | |
| Urabee et al. | Extraction methods of Alhagi Maurorum (camel thorn) and its therapeutic applications | |
| RU2213570C2 (en) | Curative-prophylactic agent from linden leaves folia tilia and method for preparing extractive substances | |
| JPH11302180A (en) | Antiulcer medicine | |
| KR0163813B1 (en) | Extraction and Purification of Active Active Ingredients from Phosphorus and Herbal Composition Containing the Extracts | |
| KR100847440B1 (en) | Complex herbal medicine for the prevention and treatment of inflammatory diseases | |
| KR100672036B1 (en) | Asthma Treatments with Honey Extract | |
| KR100552991B1 (en) | Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts | |
| KR100836559B1 (en) | Pyrola japonica Klenze extracts compositions for treating or preventing inflammatory diseases | |
| US20050142227A1 (en) | Herbal composition for gastrointestinal disorders | |
| RU2665968C1 (en) | Method for obtaining an agent of choleretic, anti-inflammatory and antioxidant activity | |
| JP2009269896A (en) | Raw material of anti-diabetic food or medicine, and anti-diabetic food or medicine | |
| US6800304B2 (en) | Anti-ulcer pharmaceutical composition and the preparation thereof | |
| KR102503839B1 (en) | A preparation method of Peanut sprout extract with increased content of nucleobase | |
| AU2008300612C1 (en) | Production of leaf extracts of Pittosporum phillyraeoides and the use thereof in medicine | |
| JP2004091349A (en) | Composition for preventing and / or treating infectious diseases | |
| CN109908120B (en) | Effective component of Dryopteris stenoptera, extraction method and application thereof | |
| RU2090200C1 (en) | Method of preparing biologically active substances influencing on gastroenteric tract | |
| KR20030021714A (en) | Herb complex composition comprising anti-toxic extract ingredients and its preparing method | |
| WO2006111251A2 (en) | Hydro-alcoholic extract of butea frondosa flowers, a process for its preparation, pharmaceutical compositions containing it and its use for the treatment of ulcer | |
| CN116509921A (en) | Application of rice flower sesterterpene extract K01 in preparation of medicines for treating sepsis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U11-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 10 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 11 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20100712 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 13 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20110910 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20110910 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |